CONCORD

CONCORD DRUGS

Small Cap BSE: 538965 NSE: CONCORD
₹27.5
-0.05 (-0.18%)
As on 19 August, 2022 | 06:47

Concord Drugs Share Price

Concord Drugs Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Concord Drugs Share Returns

  • Over 1 Month 12.94%
  • Over 3 Month -2.48%
  • Over 6 Month -12.42%
  • Over 1 Year -0.54%

Concord Drugs Key Statistics

Concord Drugs Investment Rating

  • Master Rating:
  • Concord Drugs has an operating revenue of Rs. 51.30 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Concord Drugs Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 13
  • 15
  • 13
  • 10
  • 20
  • 8
  • Operating Expenses Qtr Cr
  • 12
  • 15
  • 12
  • 8
  • 18
  • 8
  • Operating Profit Qtr Cr
  • 1
  • 1
  • 1
  • 2
  • 2
  • 1
  • Depreciation Qtr Cr
  • 0
  • 0
  • 0
  • 1
  • 1
  • 0
  • Interest Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • Tax Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • Net Profit Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0

Concord Drugs Technicals

EMA & SMA

Current Price
27.5
-0.05 (-0.18%)
  • Bullish Moving Average
  • ___
  • 13
  • Bearish Moving Average
  • ___
  • 3
  • 20 Day
  • 26.29
  • 50 Day
  • 26.29
  • 100 Day
  • 27.19
  • 200 Day
  • 29.24
  • 20 Day
  • 25.69
  • 50 Day
  • 25.76
  • 100 Day
  • 27.34
  • 200 Day
  • 29.25

Concord Drugs Resistance and Support

PIVOT
₹27.45
Resistance
  • First Resistance
  • 28.05
  • Second Resistance
  • 28.55
  • Third Resistance
  • 29.15
Support
  • First Resistance
  • 26.95
  • Second Resistance
  • 26.35
  • Third Resistance
  • 25.85
  • RSI
  • 58.37
  • MFI
  • 46.53
  • MACD Single Line
  • 0.23
  • MACD
  • 0.49

Concord Drugs Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 4,984
  • 400,116
  • 80.28
  • Week
  • 5,412
  • 422,476
  • 78.07
  • 1 Month
  • 4,706
  • 411,711
  • 87.48
  • 6 Month
  • 4,532
  • 371,100
  • 81.88

Concord Drugs Result Highlights

Concord Drugs Synopsis

BSE-Medical-Diversified

Concord Drugs belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 51.36 Cr. and Equity Capital is Rs. 8.74 Cr. for the Year ended 31/03/2021. Concord Drugs Ltd. is a Public Limited Listed company incorporated on 24/04/1995 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1995PLC020093 and registration number is 020093.
  • Market Cap
  • 24
  • Sales
  • 51
  • Shares in Float
  • 0.45
  • No of funds
  • Yield
  • Book Value
  • 0.85
  • U/D Vol ratio
  • 1.1
  • LTDebt / Equity
  • 9
  • Alpha
  • 0.03
  • Beta
  • 0.59

Concord Drugs

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 49%
  • 49%
  • 49%
  • Individual Investors
  • 50.67%
  • 50.65%
  • 50.47%
  • Others
  • 0.33%
  • 0.35%
  • 0.53%

Concord Drugs Management

  • Name
  • Designation
  • Mr. S Nagi Reddy
  • Chairman & Wholetime Director
  • Mr. T Narsimha Reddy
  • Managing Director
  • Mr. S Koni Reddy
  • Executive Director & CFO
  • Ms. P Chandra Kala
  • Independent Director

Concord Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Concord Drugs Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-06
  • Quarterly Results
  • 2022-05-30
  • Audited Results
  • 2022-02-14
  • Quarterly Results
  • 2021-10-18
  • Quarterly Results
  • 2021-08-13
  • Quarterly Results

Concord Drugs FAQs

What is Share Price of Concord Drugs ?

Concord Drugs share price is ₹27 As on 19 August, 2022 | 06:33

What is the Market Cap of Concord Drugs ?

The Market Cap of Concord Drugs is ₹24 Cr As on 19 August, 2022 | 06:33

What is the P/E ratio of Concord Drugs ?

The P/E ratio of Concord Drugs is 22 As on 19 August, 2022 | 06:33

What is the PB ratio of Concord Drugs ?

The PB ratio of Concord Drugs is 0.8 As on 19 August, 2022 | 06:33

Q1FY23